Table 3.
Mortality‐Related Events at 2 Years After TAVR
| Statin, n (%) | No Statin, n (%) | HR (95% CI) | P Value | |
|---|---|---|---|---|
| Death | ||||
| All‐cause | 79 (18.1) | 113 (24.5) | 0.65 (0.49, 0.87) | 0.004 |
| Cardiovascular | 46 (10.4) | 65 (14.3) | 0.66 (0.46, 0.96) | 0.030 |
| Noncardiovascular | 33 (8.6) | 48 (11.9) | 0.64 (0.41, 0.99) | 0.045 |
| Cardiovascular deaths | ||||
| Procedure related | 2 (0.3) | 1 (0.2) | 1.95 (0.18, 21.42) | 0.58 |
| Cardiac disease | 11 (3.0) | 28 (6.7) | 0.37 (0.18, 0.73) | 0.004 |
| Non‐cardiovascular condition | 9 (2.1) | 9 (2.5) | 0.93 (0.37, 2.36) | 0.88 |
| Unknown | 24 (5.4) | 26 (5.4) | 0.86 (0.49, 1.52) | 0.61 |
| Noncardiovascular deaths | ||||
| Infectious | 11 (2.7) | 27 (6.6) | 0.38 (0.19, 0.76) | 0.006 |
| Pulmonary | 11 (3.3) | 5 (1.6) | 2.03 (0.70, 5.88) | 0.19 |
| Malignancy | 2 (0.3) | 9 (2.3) | 0.21 (0.04, 0.96) | 0.04 |
| Accidental/trauma | 2 (0.6) | 2 (0.3) | 0.93 (0.13, 6.47) | 0.94 |
| Renal causes | 4 (1.2) | 1 (0.5) | 3.64 (0.41, 32.73) | 0.25 |
HR indicates hazard ratio; TAVR, transaortic valve replacement.